U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13N5O4
Molecular Weight 255.2306
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANCICLOVIR

SMILES

NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1

InChI

InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N
InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)

HIDE SMILES / InChI

Molecular Formula C9H13N5O4
Molecular Weight 255.2306
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ganciclovir is a synthetic acyclic nucleoside analogue of 2'-deoxyguanosine active against cytomegalovirus. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in humans. To achieve anti-CMV activity, ganciclovir is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate concentrations may be 100-fold greater in CMV-infected than in uninfected cells, indicating preferential phosphorylation in infected cells. Ganciclovir triphosphate, once formed, persists for days in the CMV-infected cell. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by (1) competitive inhibition of viral DNA polymerases; and (2) incorporation into viral DNA, resulting in eventual termination of viral DNA elongation. Ganciclovir is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the treatment of acute herpetic keratitis.

Originator

Curator's Comment: The first synthesis of ganciclovir was reported by Julien Verheyden and John Martin at Syntex Research in California in 1980 and is marketed as sodium salt (Ganciclovir sodium) under the trade names Cytovene and Cymevene.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08546
Gene ID: NA
Gene Symbol: UL54
Target Organism: Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5)
0.08 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZIRGAN

Approved Use

ZIRGAN is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Launch Date

1995
Primary
CYTOVENE

Approved Use

CYTOVENE-IV is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). CYTOVENE-IV is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease.

Launch Date

1994
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

Launch Date

2001
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.8 mg/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
13.3 μg/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.4 mg × h/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
53.8 μg × h/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.2 h
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 6 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 6 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 6 times / day
Sources:
unhealthy, 37.4
n = 19
Health Status: unhealthy
Condition: AIDS
Age Group: 37.4
Population Size: 19
Sources:
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (18%)
Thrombocytopenia (4%)
Anemia (severe, 4%)
Renal impairment (4%)
Sources:
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
n = 36
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 7.4 years (range: 0.5-16.9 years)
Population Size: 36
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (22%)
Sources:
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Other AEs: Fever, Infection...
Other AEs:
Fever (48%)
Infection (13%)
Chills (10%)
Sepsis (15%)
Diarrhea (44%)
Anorexia (14%)
Vomiting (13%)
Leukopenia (41%)
Anemia (25%)
Thrombocytopenia (6%)
Neuropathy (9%)
Sweating (12%)
Pruritus (5%)
Catheter infection (9%)
Catheter sepsis (8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Neutropenia 18%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Renal impairment 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Thrombocytopenia 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Anemia severe, 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Neutropenia 22%
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
n = 36
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 7.4 years (range: 0.5-16.9 years)
Population Size: 36
Sources:
Chills 10%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Sweating 12%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Infection 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Vomiting 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anorexia 14%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Sepsis 15%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anemia 25%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Leukopenia 41%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Diarrhea 44%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Fever 48%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Pruritus 5%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Thrombocytopenia 6%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Catheter sepsis 8%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Catheter infection 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Neuropathy 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
PubMed

PubMed

TitleDatePubMed
Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
1999
Synthesis of 4-substituted imidazo[4,5-d][1,2,3]triazine (2-azapurine)nucleosides.
2000 Jan-Feb
In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections.
2000 Jun
Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles.
2000 Jun 15
Synthesis and enantioselectivity of the antiviral effects of (R,Z)-,(S,Z)-methylenecyclopropane analogues of purine nucleosides and phosphoralaninate prodrugs: influence of heterocyclic base, type of virus and host cells.
2000 May
Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.
2000 Oct
Guanosine analogues as anti-herpesvirus agents.
2000 Oct-Dec
Prophylaxis against herpesvirus infections in transplant recipients.
2001
Pharmacokinetics of the ganciclovir implant in the silicone-filled eye.
2001
Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector.
2001 Apr
Cytological monitoring of peripheral blood, bronchoalveolar lavage fluid, and transbronchial biopsy specimens during acute rejection and cytomegalovirus infection in lung and heart--lung allograft recipients.
2001 Apr
Suspension of anticytomegalovirus maintenance therapy following immune recovery due to highly active antiretroviral therapy.
2001 Apr
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
2001 Apr 1
Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
2001 Apr 15
A time to live, a time to die.
2001 Apr 15
Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity.
2001 Feb
[Cytomegalovirus rhombencephalomyelitis in an immunocompetent subject].
2001 Feb
Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells.
2001 Feb
Effect of the complexation with cyclodextrins on the in vitro antiviral activity of ganciclovir against human cytomegalovirus.
2001 Feb
Genetic risks of antiviral nucleoside analogues--a survey.
2001 Feb
Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: diagnosis by fine-needle aspiration biopsy.
2001 Feb
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
2001 Feb
Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.
2001 Feb 15
Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
2001 Feb 15
A tightly regulated immortalized human fetal hepatocyte cell line to develop a bioartificial liver.
2001 Feb-Mar
Prophylactic antiviral therapy in CMV high-risk liver transplant recipients.
2001 Feb-Mar
Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone.
2001 Feb-Mar
Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment.
2001 Jan
Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system.
2001 Jan
Antiviral drugs in chronic hepatitis B: review and meta-analysis.
2001 Jan
Recurrent disseminated herpes zoster and cytomegalic perianal ulcer: a case report and review of the literature.
2001 Jan
Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and.
2001 Jan
[Perspectives on postgenome medicine: Gene therapy for brain tumors].
2001 Jan
Cytomegalovirus hemorrhagic gastritis.
2001 Jan
Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties.
2001 Jan
Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications.
2001 Jan 1
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.
2001 Jan 1
Disseminated cytomegalovirus disease in hosts without acquired immunodeficiency syndrome and without an organ transplant.
2001 Jan 15
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
2001 Jan 15
Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
2001 Jan 15
Human beta-herpesvirus interactions in solid organ transplant recipients.
2001 Jan 15
Toxic megacolon: remember cytomegalovirus.
2001 Mar
Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient.
2001 Mar
The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host.
2001 Mar
Frosted branch angiitis in a child with HIV infection.
2001 Mar
Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
2001 Mar 1
Reactivity of valganciclovir in aqueous solution.
2005 Oct
The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review.
2017 Mar
A 42-Year-Old Woman With Anemia, Shock, and Ischemic Stroke After Lung Transplantation.
2017 Mar
Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention.
2017 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Ganciclovir can be used as ophthalmic gel 1 drop in the affected eye 5 times per day in patients with acute herpetic keratitis.
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: The median concentration of ganciclovir that inhibits CMV replication (IC50) in vitro (laboratory strains or clinical isolates) has ranged from 0.02 to 3.48 ug/mL.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:04:12 GMT 2023
Edited
by admin
on Fri Dec 15 15:04:12 GMT 2023
Record UNII
P9G3CKZ4P5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GANCICLOVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BW 759U
Code English
GANCICLOVIR [HSDB]
Common Name English
GANCICLOVIR [EP IMPURITY]
Common Name English
GANCICLOVIR [EMA EPAR]
Common Name English
9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine
Systematic Name English
Ganciclovir [WHO-DD]
Common Name English
VALGANCICLOVIR HYDROCHLORIDE IMPURITY A [USP IMPURITY]
Common Name English
GANCICLOVIR [USAN]
Common Name English
GANCICLOVIR [USP MONOGRAPH]
Common Name English
6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)-
Systematic Name English
GANCICLOVIR [MART.]
Common Name English
VITRASERT
Brand Name English
ZIRGAN
Brand Name English
GANCICLOVIR [ORANGE BOOK]
Common Name English
RS-21592
Code English
BW-759U
Code English
ganciclovir [INN]
Common Name English
GANCICLOVIR [EP MONOGRAPH]
Common Name English
GANCICLOVIR [VANDF]
Common Name English
NSC-759656
Code English
GANCICLOVIR [MI]
Common Name English
GANCICLOVIR [USP-RS]
Common Name English
GANCICLOVIR [JAN]
Common Name English
GANCYCLOVIR
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 237607
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NCI_THESAURUS C1556
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NCI_THESAURUS C29575
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NDF-RT N0000020060
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
LIVERTOX NBK548760
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NDF-RT N0000175461
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
EMA ASSESSMENT REPORTS VITRASERT IMPLANT (WITHDRAWN: CYTOMEGALOVIRUS RETINITIS)
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NDF-RT N0000175466
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
WHO-VATC QS01AD09
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
FDA ORPHAN DRUG 5885
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NDF-RT N0000175459
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NCI_THESAURUS C281
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
WHO-ATC J05AB06
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
WHO-VATC QJ05AB06
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NDF-RT N0000175459
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
WHO-ATC S01AD09
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
FDA ORPHAN DRUG 86494
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
NDF-RT N0000175459
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
Code System Code Type Description
CHEBI
465284
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
SMS_ID
100000085455
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
EVMPD
SUB07881MIG
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
PUBCHEM
135398740
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
DRUG CENTRAL
1277
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
USAN
W-148
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID8041032
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
DRUG BANK
DB01004
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
RS_ITEM_NUM
1288306
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
NCI_THESAURUS
C517
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
DAILYMED
P9G3CKZ4P5
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL182
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
NSC
759656
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
RXCUI
4678
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY RxNorm
LACTMED
Ganciclovir
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
INN
6023
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
MERCK INDEX
m5663
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY Merck Index
FDA UNII
P9G3CKZ4P5
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
HSDB
6512
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
CAS
82410-32-0
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
MESH
D015774
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
WIKIPEDIA
GANCICLOVIR
Created by admin on Fri Dec 15 15:04:12 GMT 2023 , Edited by admin on Fri Dec 15 15:04:12 GMT 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Vmax
TARGET ORGANISM->INHIBITOR
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
Km
TRANSPORTER -> SUBSTRATE
Vmax
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TARGET ORGANISM->INHIBITOR
TRANSPORTER -> SUBSTRATE
Km
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY